Aceminib used to treat chronic myelogenous leukemia in adults

Asciminib has demonstrated remarkable efficacy and safety in the treatment of adult chronic myelogenous leukemia (CML), bringing new hope to patients.

Aximini is mainly used to treat Philadelphia chromosome-positive (Ph+) CML patients, especially those who have received Patients who have been treated with two or more tyrosine kinase inhibitors (TKI), and patients with the T315I mutation. In clinical trials, Aceminib has shown impressive efficacy. For example, in an open-label, Phase 1 trial, T315Imutant CMLchronic phase (CP) patients, after aceminib monotherapy, 69.6% were still taking the drug after a median exposure of approximately 4 years. In addition, 61.3% of patients achieved a molecular response of BCR-ABL1≤1%, demonstrating the excellent performance of aceminib in the treatment of CML.

Asiminib is a novel BCR-ABL1 ATP binding site mutationSTAMP inhibitor. It can effectively alleviate TKIs resistance to CML, improve efficacy, and improve patient prognosis. Compared with traditional TKI, Aceminib has a more precise mechanism of action and can directly inhibit abnormal proteins in cancer cells, thereby reducing the proliferation and spread of leukemia cells.

In terms of safety, Aceminib was also well tolerated. The incidence of adverse events in clinical trials was relatively low in patients treated with aceminib compared with comparators. Common adverse reactions mainly include upper respiratory tract infection, musculoskeletal pain, joint pain, etc., but these are mild and controllable. In addition, the side effects of aximini are relatively mild and can be tolerated by most patients.

In addition to its significant efficacy and good safety profile, aceminib can effectively improve patients' quality of life. Due to its precise mechanism of action and low incidence of side effects, patients can maintain a better living condition and reduce the pain caused by the disease during the treatment process.